论文部分内容阅读
[目的]探讨胰高血糖素样肽-2(GLP-2)在SAP肠黏膜免疫屏障功能障碍中的保护作用。[方法]健康纯系SD大鼠30只,随机分为3组:对照组(假手术组),胰腺炎组(SAP组),治疗组(SAP+GLP-2组)。采用胰管逆行注射3%牛磺胆酸钠溶液制作重症胰腺炎模型,治疗组制作胰腺炎模型后,皮下注射GLP-2类似物0.1 mg/kg 3 d。3 d后处死大鼠,HE染色切片光镜观察小肠黏膜改变;放射免疫法分析肠黏膜中sIgA含量改变。[结果]急性胰腺炎模型组黏膜层出现明显病理改变;与胰腺炎组相比较,治疗组小肠黏膜损伤显著减轻,黏膜轻度水肿层,绒毛较长,数量较多,上皮细胞基本完整,断裂现象不明显,绒毛固有层淋巴细胞、浆细胞等免疫细胞数量较多,固有层仅有少量炎细胞浸润,小肠腺加深,数量较多;胰腺炎组sIgA比对照组显著减少(0.187±0.028 g/L,0.846±0.140 g/L,P﹤0.05);治疗组sIgA比胰腺炎组增高显著(0.703±0.138 g/L,0.187±0.028 g/L,P﹤0.05)。[结论]GLP-2对SAP肠黏膜免疫屏障功能障碍具有一定保护作用。
[Objective] To explore the protective effect of glucagon-like peptide-2 (GLP-2) on immune barrier dysfunction in SAP intestinal mucosa. [Method] Thirty healthy healthy SD rats were randomly divided into three groups: control group (sham operation group), pancreatitis group (SAP group) and treatment group (SAP + GLP-2 group). The pancreatic duct was retrogradely injected with 3% sodium taurocholate solution to make severe pancreatitis model. After the pancreatitis model was made in the treatment group, GLP-2 analogue 0.1 mg / kg was injected subcutaneously for 3 days. After 3 days, the rats were sacrificed, HE staining sections were observed light microscopic changes of mucosa; radioimmunoassay analysis sIgA changes in intestinal mucosa. [Results] The pathological changes of the mucosa in the acute pancreatitis model group were obvious. Compared with the pancreatitis group, the lesion in the intestinal mucosa of the treated group was significantly alleviated. The mild edema layer of the acute pancreatitis model had longer and more number of villi, the epithelial cells were basically intact, The phenomenon was not obvious. The number of immune cells such as lymphocytes and plasma cells in the lamina propria was higher than that in the control group (0.187 ± 0.028 g, P <0.05), but only a small amount of inflammatory cells infiltrated into the lamina propria. /L0.846 ± 0.140 g / L, P <0.05). The sIgA of the treatment group was significantly higher than that of the pancreatitis group (0.703 ± 0.138 g / L, 0.187 ± 0.028 g / L, P <0.05). [Conclusion] GLP-2 has a protective effect on the intestinal mucosal immune barrier dysfunction.